Want to see JBIO full AI Analyst Report?
Top Page
Jade Biosciences
(NASDAQ:JBIO)
Select Model
Select Model
Rating:55Neutral
Price Target:
$22.50
▲(3.02% Upside)
Action:Reiterated
Date:08/11/26
JBIO scores as a mid-risk, development-stage biotech: the dominant factor is weak financial performance driven by zero revenue and a rapidly increasing cash burn despite a strong, low-debt balance sheet. Technicals are supportive with the stock trading above key moving averages and positive momentum, and corporate updates (clinical progress and added funding) are constructive. Traditional valuation signals remain unfavorable due to losses (negative P/E) and no provided dividend yield.
Positive Factors
Low leverage and strong capitalization
Jade’s minimal debt and large equity base provide durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. Low leverage reduces default risk, supports investment in R&D and manufacturing scale-up, and preserves strategic optionality as trials advance.
Negative Factors
Pre-revenue with widening net losses
Jade remains a development-stage, pre-revenue company with materially negative and widening net losses. Without commercial revenue, the business depends on capital markets and milestone receipts; persistent losses can erode equity and limit strategic flexibility if clinical timelines slip or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and strong capitalization
Jade’s minimal debt and large equity base provide durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. Low leverage reduces default risk, supports investment in R&D and manufacturing scale-up, and preserves strategic optionality as trials advance.
Read all positive factors
Jade Biosciences (JBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.39B
Dividend YieldN/A
Average Volume (3M)1.18M
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue GrowthN/A
EPS Growth91.41%
CountryUS
Employees55
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.75
Shares Outstanding63,597,385
10 Day Avg. Volume894,398
30 Day Avg. Volume1,180,703
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.05
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$50.13Price Target Upside129.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.62
Revenue Forecast (FY)N/A
Jade Biosciences Business Overview & Revenue Model
Company Description
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specific...
How the Company Makes Money
null...
Jade Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
74
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -18.00K | 0.00 | -282.00K | -96.00K | -68.00K | -15.00K |
| EBITDA | -156.28M | -127.33M | -69.29M | -75.37M | -51.42M | -22.95M |
| Net Income | -153.24M | -127.41M | -69.63M | -75.52M | -51.51M | -22.96M |
Balance Sheet | ||||||
| Total Assets | 472.11M | 349.78M | 80.33M | 127.42M | 135.30M | 175.36M |
| Cash, Cash Equivalents and Short-Term Investments | 461.20M | 336.16M | 78.62M | 122.44M | 129.22M | 167.38M |
| Total Debt | 628.00K | 724.00K | 417.00K | 675.00K | 1.09M | 574.00K |
| Total Liabilities | 32.20M | 17.26M | 3.90M | 17.96M | 8.56M | 2.94M |
| Stockholders Equity | 439.92M | 332.52M | 76.43M | 109.46M | 126.74M | 172.42M |
Cash Flow | ||||||
| Free Cash Flow | -123.57M | -94.89M | -71.20M | -56.92M | -39.32M | -27.58M |
| Operating Cash Flow | -123.51M | -94.69M | -71.20M | -56.78M | -39.12M | -27.40M |
| Investing Cash Flow | -352.97M | -247.01M | 56.03M | 11.88M | 6.93M | -113.43M |
| Financing Cash Flow | 362.89M | 360.77M | 25.43M | 46.00M | 396.00K | 190.46M |
Jade Biosciences Technical Analysis
Neutral
21.84
Price Trends
21.14
Positive
21.18
Positive
17.64
Positive
Market Momentum
0.26
Positive
47.79
Neutral
24.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JBIO, the sentiment is Neutral. The current price of 21.84 is below the 20-day moving average (MA) of 21.93, above the 50-day MA of 21.14, and above the 200-day MA of 17.64, indicating a neutral trend. The MACD of 0.26 indicates Positive momentum. The RSI at 47.79 is Neutral, neither overbought nor oversold. The STOCH value of 24.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JBIO.
Jade Biosciences Risk Analysis
Jade Biosciences disclosed 74 risk factors in its most recent earnings report. Jade Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Jade Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $737.21M | -7.87 | -35.26% | ― | ― | -13.09% | |
55 Neutral | $1.39B | -7.76 | -49.11% | ― | ― | 91.41% | |
53 Neutral | $194.79M | -1.34 | -938.20% | ― | 159.29% | -7.39% | |
52 Neutral | $402.39M | -9.72 | 21.48% | ― | ― | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $247.71M | -5.40 | -94.14% | ― | -0.11% | -13.99% | |
40 Underperform | $57.16M | -0.89 | -69.20% | ― | ― | -69.60% |
* Healthcare Sector Average
JBIO
Jade Biosciences
21.33
13.25
163.99%
GALT
Galectin Therapeutics
4.15
-0.10
-2.35%
IMMP
Immutep
0.38
-1.28
-77.11%
CLLS
Cellectis SA
3.42
0.82
31.54%
TECX
Tectonic Therapeutic
35.97
10.40
40.67%
HUMA
Humacyte
0.68
-0.90
-56.90%
Jade Biosciences Corporate Events
Business Operations and Strategy
Jade Biosciences Secures Exclusive Antibody License Agreement
Positive
Jul 1, 2026
On June 29, 2026, Jade Biosciences entered into a worldwide, exclusive license agreement with Paragon Therapeutics for certain monospecific antibodies targeting an undisclosed biological target, covering prophylaxis, palliation, treatment and diag...
Business Operations and StrategyExecutive/Board Changes
Jade Biosciences Adds Veteran Biopharma Leader to Board
Positive
Jun 26, 2026
On June 25, 2026, Jade Biosciences appointed veteran biopharmaceutical executive Mark Eisner, M.D., M.P.H., as a Class I director on its board and a member of the Nominating and Corporate Governance Committee, with his term running through the 202...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Jade Biosciences Shareholders Approve Governance and Audit Measures
Positive
Jun 11, 2026
Jade Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, where shareholders elected two Class II directors, Christopher Cain, Ph.D., and Tom Frohlich, to serve on the board until the 2029 Annual Meeting. Stockholders al...
Business Operations and StrategyPrivate Placements and Financing
Jade Biosciences Launches Major Underwritten Equity Offering
Positive
Jun 4, 2026
On June 3, 2026, Jade Biosciences, Inc. entered into an underwriting agreement with a syndicate led by Jefferies, TD Securities and UBS for an underwritten public offering of 10,000,000 common shares at $15.00 each, with underwriters purchasing at...
Business Operations and StrategyProduct-Related Announcements
Jade Biosciences Reports Positive Phase 1 JADE101 Results
Positive
Jun 1, 2026
On June 1, 2026, Jade Biosciences reported interim results from a Phase 1 double-blind, placebo-controlled trial of JADE101 in 32 healthy volunteers, showing single subcutaneous doses up to 1,400 mg were well tolerated with no serious adverse even...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.